Chinese researchers from Huazhong University of Science and Technology have developed a novel carbonic anhydrase IX (CAIX)-targeting radiotracer, [68Ga]NXK-44, for the imaging of hypoxic tumors and renal cell carcinoma (RCC).
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer.
Researchers from Sagittide Therapeutics Co. Ltd. and Shanghai Jiao Tong University have presented results of early studies with a novel MUC1-C-targeted near-infrared imaging agent – SAG-602 – for fluorescence-guided surgery of cancer.
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, Chinese Academy of Medical Sciences and Peking Union Medical College scientists co-presented a carbonic anhydrase IX (CAIX)-targeting 68Ga/177Lu theranostic pair for clear cell renal cell carcinoma (ccRCC) and its preclinical evaluation.
Researchers at Ileadbms Co. Ltd. have announced promising results of their novel drug IL-21120033 in a preclinical model of rheumatoid arthritis. The drug acts as a selective agonist of the chemokine receptor CXCR7.
PRMT1 is a key enzyme that catalyzes asymmetric dimethylation of arginine residues and overexpressed in various cancers and inflammatory diseases. While current PRMT1 inhibitors lack specificity and effectiveness, targeted degradation of PRMT1 offers a potential strategy to treat PRMT1-driven conditions and explore its nonenzymatic roles.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra, leading to clinical symptoms such as tremors, rigidity, bradykinesia and postural instability.
Researchers at North China Electric Power University and collaborators have developed novel radiolabels for the membrane-bound monoamine oxidase-B that feature a coumarin core.
Researchers from Fudan University and their collaborators reported the synthesis and preclinical characterization of novel Bruton’s tyrosine kinase (BTK)-targeting proteolysis-targeting chimeras (PROTACs) based on ARQ-531, a potent, reversible, noncovalent BTK inhibitor.
Tumors with high levels of microsatellite instability (MSI-H), such as some subsets of colorectal, endometrial and gastric cancers, are associated with a hypermutated phenotype and a specific dependency on the WRN gene. Pharmacologic inhibition of WRN has been shown to selectively impair the viability of MSI-H cancer cells, effectively blocking tumor growth while sparing microsatellite-stable (MSS) cells.
RSS
